← 產業報告目錄
Myasthenia Gravis Treatment Market Size, Share & Trends Analysis Report By Treatment (Medication, Surgery, Others), By End-Use (Hospitals, Clinics, Others), By Region, And By Segment Forecasts, 2025-2034
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-01-19頁數 179報告編號 INSIGHTACE-528331fb40
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
The Myasthenia Gravis Treatment Market on a global scale was estimated at USD 1.60 Bn in 2024 and is poised to attain USD 3.34 Bn by 2034, with a projected CAGR of 7.8% between 2025 and 2034.
The Myasthenia Gravis Treatment sector involves an uncommon neuromuscular illness characterized by gradual weakness of the muscles of the face, neck, upper and lower body, and respiratory system. This domain has witnessed notable transformation owing to technological breakthroughs and shifting healthcare dynamics.
Several factors contribute to this trajectory, including heightened call for next-generation products, expanding applications across diverse end-use sectors, and supportive government initiatives.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, driven by rapid industrialization and expanding end-user bases.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Myasthenia Gravis Treatment Market Snapshot
Chapter 4. Global Myasthenia Gravis Treatment Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Treatment Estimates & Trend Analysis
5.1. By Treatment, & Market Share, 2024 to 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Treatment:
5.2.1. Medication
5.2.2. Surgery
5.2.3. Others
Chapter 6. Market Segmentation 2: By End-Use Estimates & Trend Analysis
6.1. By End-Use & Market Share, 2024 to 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By End-Use:
6.2.1. Hospitals
6.2.2. Clinics
6.2.3. Others
Chapter 7. Myasthenia Gravis Treatment Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Myasthenia Gravis Treatment Market revenue (US$ Million) estimates and forecasts By Treatment, 2021-2034
7.1.2. North America Myasthenia Gravis Treatment Market revenue (US$ Million) estimates and forecasts By End-Use, 2021-2034
7.1.3. North America Myasthenia Gravis Treatment Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
7.2. Europe
7.2.1. Europe Myasthenia Gravis Treatment Market revenue (US$ Million) By Treatment, 2021-2034
7.2.2. Europe Myasthenia Gravis Treatment Market revenue (US$ Million) By End-Use, 2021-2034
7.2.3. Europe Myasthenia Gravis Treatment Market revenue (US$ Million) by country, 2021-2034
7.3. Asia Pacific
7.3.1. Asia Pacific Myasthenia Gravis Treatment Market revenue (US$ Million) By Treatment, 2021-2034
7.3.2. Asia Pacific Myasthenia Gravis Treatment Market revenue (US$ Million) By End-Use, 2021-2034
7.3.3. Asia Pacific Myasthenia Gravis Treatment Market revenue (US$ Million) by country, 2021-2034
7.4. Latin America
7.4.1. Latin America Myasthenia Gravis Treatment Market revenue (US$ Million) By Treatment, (US$ Million) 2021-2034
7.4.2. Latin America Myasthenia Gravis Treatment Market revenue (US$ Million) By End-Use, (US$ Million) 2021-2034
7.4.3. Latin America Myasthenia Gravis Treatment Market revenue (US$ Million) by country, 2021-2034
7.5. Middle East & Africa
7.5.1. Middle East & Africa Myasthenia Gravis Treatment Market revenue (US$ Million) By Treatment, (US$ Million) 2021-2034
7.5.2. Middle East & Africa Myasthenia Gravis Treatment Market revenue (US$ Million) By End-Use, (US$ Million) 2021-2034
7.5.3. Middle East & Africa Myasthenia Gravis Treatment Market revenue (US$ Million) by country, 2021-2034
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Alexion Pharmaceutical Inc.;
8.2.2. Grifols SA;
8.2.3. Avadel Pharmaceuticals plc. Novartis AG;
8.2.4. Pfizer; Inc.;
8.2.5. AbbVie Inc.;
8.2.6. F. Hoffmann-La Roche Ltd.;
8.2.7. GlaxoSmithKline plc;
8.2.8. Bausch Health Companies Inc.;
8.2.9. Shire plc.
8.2.10. Other Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們